// App-Quantinova.ai

TPS622 : A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.

Researchers

Presenter

  • Robert E. Coleman

Principal Investigators

  • Rui Li

  • Amrita G. Sawhney

  • Oana Petrenciuc

  • Hope S. Rugo

Medical Centers

  • University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Leptomeningeal Metastasis

  • Bone metastases

  • Breast cancer

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Alpharadin

  • Everolimus

  • Radium-223 Dichloride

  • Denosumab

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02258464

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved